Wednesday, July 8, 2026

biotech · Type 1 Diabetes Mellitus · Dehydration · HALO

HALOZYME THERAPEUTICS

HALOZYME THERAPEUTICS is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker HALO. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Dehydration, Pancreatic Ductal Adeno

12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
Status
Public
HQ
12390 El Camino Real, San Diego, California 92130, US
Founded
2021
Employees
530
Programs
45
Drugs
33
Patents
70
Clinical program

SC HYLENEX and Ceftriaxone

Phase 1 · small molecule · Healthy

SC HYLENEX and Ceftriaxone for Healthy is a Phase 1 program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All HALOZYME THERAPEUTICS, INC. projects Phase 1 small molecule completed

Internal code 1838-004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
HALOZYME THERAPEUTICS, INC.
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
completed
Trials
1